Role of Extraretroperitoneal Surgery in Patients with Metastatic Germ Cell Tumors

Hu, Brian; Daneshmand, Siamak

doi:10.1016/j.ucl.2015.04.011

Cited by 15 publications

(4 citation statements)

References 42 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A majority can be successfully managed with systemic therapy. However, surgery is recommended in patients with ERP disease and normal tumor markers, due to risk of harboring teratoma or viable tumor [32]. The management of ERP is challenging owing to the higher morbidity associated with concurrent resection of ERP at time of RPLND.…”

Section: Management Of Extraretroperitoneal Diseasementioning

confidence: 99%

Intricacies of retroperitoneal lymph node dissection for testis cancer

Alsyouf

Daneshmand

2021

Current Opinion in Urology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewRetroperitoneal lymph node dissection (RPLND) and retroperitoneal tumor resection for germ cell cancer are complex operations requiring experience and expertise in surgical techniques necessary to achieve complete resection while minimizing morbidity. This article reviews the intricacies of RPLND for testis cancer. Recent findingsSurgical management of advanced testis cancer begins with an intimate understanding of retroperitoneal anatomy and the various techniques necessary to safely extirpate tumors. Preoperatively patients should undergo comprehensive counseling and obtain up-to-date imaging along with tumor markers to assist in surgical planning and evaluation of extraretroperitoneal (ERP) disease. Surgeons must be well versed in nerve-sparing techniques to maintain ejaculatory function. Newer techniques using a midline extraperitoneal technique minimizes morbidity and length of hospital stay. Special consideration should be given to the possibility of encountering ERP disease in advanced germ cell tumors, with management of these cases in tertiary care centers with multidisciplinary teams.

show abstract

Section: Management Of Extraretroperitoneal Diseasementioning

confidence: 99%

Intricacies of retroperitoneal lymph node dissection for testis cancer

Alsyouf

Daneshmand

2021

Current Opinion in Urology

Self Cite

View full text Add to dashboard Cite

show abstract

“…in case of negative tumor markers and residual disease, all sites of residual retroperitoneal and extraperitoneal disease should be surgically removed. unlike lung, liver and neck disease, the role of surgery in patients with brain metastasis is less common because of the efficacy of new radiation techniques combined 25 . Patients with stage iii seminoma are evaluated with tumor markers and PeT/CT scan 6-8 weeks after primary treatment with chemotherapy.…”

Section: Primary Treatment Of Intermediate/poor-risk Diseasementioning

confidence: 99%

Treatment of Germ Cell Testicular Cancer

Kunac

Gnjidić

Golubić

et al. 2020

ACC

View full text Add to dashboard Cite

germ cell testicular cancer (gCTC) is a malignant neoplasm derived from the primordial germ cell. Although it accounts for approximately 1% of all malignancies in men, it is the most common cancer of younger male population, with the highest incidence between ages 15 and 35. Testicular cancer incidence rate has risen globally over the past several decades, with the average increase in the incidence of testicular cancer in Croatia of 7% per annum from the year 1983 to 2007. Two main groups are seminomas and non-seminomas, each accounting for 50% of cases, and they differ in treatment modalities and response to therapy. Despite increase in the incidence rate, a promising circumstance is that gCTC has become a model of curable cancer. Because of advances in diagnostic procedures, sophisticated radiation techniques and especially the introduction of cisplatin based chemotherapy protocols together with advanced postchemotherapy surgical techniques, curability is expected in about 95% of all patients diagnosed with testicular cancer and over 70% of patients with advanced disease. in this review, we will focus on treatment strategies of primary gCTC.

show abstract

“…[2][3][4] Postojanje ostatne tumorske mase ≥ 1 cm (nakon prikaza CT-om) uz normalne vrijednosti tumorskih biljega indicira kiruršku resekciju svih ostatnih masa (IVA). [2][3][4]14 Ako se histološkom analizom u reseciranim ostatnim masama nađu samo nekrotično tkivo i/ili teratom, preporučuje se praćenje. Nađu li se stanice koriokarcinoma, embrionalnog raka, tumora žumanjčane vreće ili seminoma, indiciraju se dva ciklusa postoperativne kemoterapije prema protokolima PEI ili TIP (paklitaksel, ifosfamid, cisplatina).…”

Section: Postupak Nakon Završene Kemoterapije Pri II I Iii Stadiju unclassified

“…Pri ostatnoj tumorskoj masi (nakon nalaza CT-a) većoj od 1 cm nakon provedene kemoterapije uz normalne vrijednosti tumorskih biljega kod neseminomskih tumora indicira se spasonosna (salvage) kirurška resekcija svih ostatnih tumorskih masa. 2,3,14,17 Zbog složenosti odluku o liječenju salvage kemoterapijom mora donijeti multidisciplinarni tim ekspertnog centra.…”

Section: Postupak Nakon Završene Kemoterapije Pri II I Iii Stadiju unclassified

Clinical guidelines for diagnostics, treatment and monitoring of patients with testicular cancer

Gamulin

Bulimbašić

Jazvić

et al. 2019

View full text Add to dashboard Cite

Role of Extraretroperitoneal Surgery in Patients with Metastatic Germ Cell Tumors

Cited by 15 publications

References 42 publications

Intricacies of retroperitoneal lymph node dissection for testis cancer

Intricacies of retroperitoneal lymph node dissection for testis cancer

Treatment of Germ Cell Testicular Cancer

Clinical guidelines for diagnostics, treatment and monitoring of patients with testicular cancer

Contact Info

Product

Resources

About